Intrauterine exposure to carbamazepine and specific congenital malformations: Systematic review and case-control study

BMJ (Online)

Volumn 341, Issue 7785, 2010, Pages 1261-

  Jentink, Janneke ^a   Dolk, Helen ^b   Loane, Maria A ^b   Morris, Joan K ^c   Wellesley, Diana ^d   Garne, Ester ^e   De Jong van Den Berg, Lolkje ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e KOLDING HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENOBARBITAL; VALPROIC ACID;

CASE CONTROL STUDY; CLEFT LIP; CONGENITAL MALFORMATION; DIAPHRAGM HERNIA; FETUS; FIRST TRIMESTER PREGNANCY; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPOSPADIAS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SPINA BIFIDA; SYSTEMATIC REVIEW; EPILEPSY; EUROPE; FEMALE; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; RISK FACTOR;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; CARBAMAZEPINE; CASE-CONTROL STUDIES; EPILEPSY; EUROPE; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; PREVALENCE; RISK FACTORS;

EID: 78650021238     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c6581     Document Type: Review

References (20)

1. Kini U, Adab N, Vinten J, Fryer A, Clayton-Smith J, Liverpool and Manchester Neurodevelopmental Study Group. Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes. Arch Dis Child Fetal Neonatal Ed 2006;91:90-5.
2. Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, et al. In utero antiepileptic drug exposure, fetal death and malformations. Neurology 2006;67:407-12.
3. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-8.
4. Vajda FJE, Lander CM, Hitchcock A, Graham J, Solinas C, O'Brien T, et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. J Clin Neurosci 2007;14:611-7. (Pubitemid 46783493)
5. Wide K, Winbladh B, Källén B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Pædiatr 2004;93:174-6. (Pubitemid 38230710)
6. Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, et al, for the EUROCAT Antiepileptic Study Working Group. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010;362:2185-93.
7. Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 2005;4:781-6. (Pubitemid 41457294)
8. Tomson T, Perucca E, Battino D. Navigating toward fetal andmaternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004;45:1171-5. (Pubitemid 39350328)
9. Dolk H, Jentink J, Loane MA, Morris JK, De Jong-van den Berg LTW, the EUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008;71:714-22.
10. EUROCAT. EUROCAT Guide 1.3 and reference documents. Instructions for the registration and surveillance of congenital anomalies. 2005. www.eurocat-network.eu/content/EUROCATGuide-1.3.pdf.
11. Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 2001;57:321-4. (Pubitemid 32667369)
12. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003;60:575-9.
13. Sabers A, Dam M, a-Rogvi-Hansen B, Boas J, Sidenius P, Laue Friis M, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004;109:9-13.
14. Samrén EB, Van Duijn CM, Koch S, Hiilesmaa VK, Klepel H, Bardy AH, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38:981-90.
15. Hernandez-Diaz S, Smith CR, Wyszynski DF, Holmes LB. Major malformations among infants exposed to carbamazepine during pregnancy (Teratology Society Abstracts). Birth Defects Res A Clin Mol 2007;79:357.
16. World Health Organization. ATC index with DDDs 2003. Guidelines for ATC classification and DDD assignment 2003. Version 13. WHO Collaborating Centre for Drug Statistics Methodology, 2003.
17. Ornoy A. Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy. Reprod Toxicol 2006;22:214-26.
18. Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: ameta-analysis of 1255 exposures. Reprod Toxicol 2002;16:9-17. (Pubitemid 34308448)
19. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database Syst Rev 2000;3:CD001030.
20. Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al. Management issues for women with epilepsy - focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes. Epilepsia 2009;50:1237-46.